RxDoctor Payments Data

Aleysia Jones

Medical · Decatur, GANPI 1952863961

Payments from drug & device makers

$4,952in general payments, 2019–2025

Across 114 payments — averaging $43.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$3K
  • Sumitomo Pharma America, Inc.$439
  • Myriad Genetic Laboratories, Inc.$415
  • Astellas Pharma US Inc$361
  • SRS Medical Systems, Inc.$234
  • Pfizer$115
  • plus $695 from 20 others

What the payments were for

  • Speaking & faculty fees$1122%
  • Travel & lodging$1,72935%
  • Food & beverage$3,01861%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,952 in reported general payments places this provider in the 80th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$22,755
Medicare patients
44
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide24$338,695
XtandiEnzalutamide19$273,193
GemtesaVibegron178$154,987
MyrbetriqMirabegron114$84,858
OrgovyxRelugolix17$46,356
Methenamine Hippurate245$12,962
Tamsulosin Hcl670$8,535
Silodosin77$5,768
Dutasteride90$4,549
Solifenacin Succinate100$2,552
Tolterodine Tartrate ErTolterodine Tartrate22$2,298
Testosterone Cypionate26$1,969
Trimethoprim40$1,901
Estradiol23$1,510
Oxybutynin Chloride ErOxybutynin Chloride70$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$361$358,051133 claims
Johnson & JohnsonErleada$34$338,69524 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$439$201,344195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 950 medical providers in Georgia.

Other medical in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →